Biogen (BIIB) Projected to Post Quarterly Earnings on Friday

Biogen (NASDAQ:BIIB) is projected to issue its Q4 2025 results before the market opens on Friday, February 6th. Analysts expect Biogen to post earnings of $1.72 per share and revenue of $2.2147 billion for the quarter. Interested persons are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Friday, February 6, 2026 at 8:30 AM ET.

Biogen (NASDAQ:BIIB) last posted its earnings results on Thursday, October 30th. The biotechnology company reported $4.81 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.89 by $0.92. Biogen had a return on equity of 14.13% and a net margin of 15.98%.The company had revenue of $2.53 billion for the quarter, compared to analysts’ expectations of $2.34 billion. During the same period last year, the business posted $4.08 earnings per share. The firm’s quarterly revenue was up 2.8% compared to the same quarter last year. On average, analysts expect Biogen to post $16 EPS for the current fiscal year and $17 EPS for the next fiscal year.

Biogen Stock Performance

Shares of BIIB opened at $176.18 on Friday. The firm has a fifty day moving average of $176.38 and a 200-day moving average of $154.29. The company has a market cap of $25.85 billion, a price-to-earnings ratio of 16.06, a price-to-earnings-growth ratio of 1.45 and a beta of 0.13. The company has a debt-to-equity ratio of 0.35, a quick ratio of 2.04 and a current ratio of 2.72. Biogen has a 1 year low of $110.04 and a 1 year high of $190.20.

Analysts Set New Price Targets

BIIB has been the subject of a number of analyst reports. Mizuho boosted their target price on shares of Biogen from $177.00 to $207.00 and gave the company an “outperform” rating in a research note on Thursday, January 8th. Citigroup lifted their price target on Biogen from $180.00 to $185.00 and gave the company a “neutral” rating in a report on Tuesday. Guggenheim boosted their price objective on Biogen from $165.00 to $185.00 in a research report on Friday, October 31st. Sanford C. Bernstein raised their target price on Biogen from $157.00 to $197.00 and gave the company a “market perform” rating in a research report on Friday, January 9th. Finally, Jefferies Financial Group lifted their target price on Biogen from $190.00 to $210.00 and gave the company a “buy” rating in a research note on Friday, November 28th. Ten equities research analysts have rated the stock with a Buy rating, fifteen have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $192.04.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the company. Advisory Services Network LLC raised its position in Biogen by 3.9% in the third quarter. Advisory Services Network LLC now owns 1,792 shares of the biotechnology company’s stock worth $251,000 after acquiring an additional 68 shares in the last quarter. CIBC Private Wealth Group LLC grew its stake in shares of Biogen by 8.1% in the 3rd quarter. CIBC Private Wealth Group LLC now owns 1,189 shares of the biotechnology company’s stock worth $167,000 after purchasing an additional 89 shares during the last quarter. Guardian Investment Management raised its holdings in shares of Biogen by 1.9% in the 3rd quarter. Guardian Investment Management now owns 5,400 shares of the biotechnology company’s stock worth $756,000 after purchasing an additional 100 shares in the last quarter. Larson Financial Group LLC lifted its stake in Biogen by 23.4% during the third quarter. Larson Financial Group LLC now owns 638 shares of the biotechnology company’s stock valued at $89,000 after purchasing an additional 121 shares during the last quarter. Finally, Northwestern Mutual Wealth Management Co. lifted its stake in Biogen by 2.2% during the third quarter. Northwestern Mutual Wealth Management Co. now owns 5,930 shares of the biotechnology company’s stock valued at $831,000 after purchasing an additional 127 shares during the last quarter. 87.93% of the stock is owned by institutional investors and hedge funds.

About Biogen

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.